Genotype-Phenotype Correlations in PMM2-CDG
- PMID: 34828263
- PMCID: PMC8620515
- DOI: 10.3390/genes12111658
Genotype-Phenotype Correlations in PMM2-CDG
Abstract
PMM2-CDG is a rare disease, causing hypoglycosylation of multiple proteins, hence preventing full functionality. So far, no direct genotype-phenotype correlations have been identified. We carried out a retrospective cohort study on 26 PMM2-CDG patients. We collected the identified genotype, as well as continuous variables indicating the disease severity (based on Nijmegen Pediatric CDG Rating Score or NPCRS) and dichotomous variables reflecting the patients' phenotype. The phenotypic effects of patients' genotype were studied using non-parametric and Chi-Square tests. Seventeen different pathogenic variants have been studied. Variants with zero enzyme activity had no significant impact on the Nijmegen score. Pathogenic variants involving the stabilization/folding domain have a significantly lower total NPCRS (p = 0.017): presence of the p.Cys241Ser mutation had a significantly lower subscore 1,3 and NPCRS (p = 0.04) and thus result in a less severe phenotype. On the other hand, variants involving the dimerization domain, p.Pro113Leu and p.Phe119Leu, resulted in a significantly higher NPCRS score (p = 0.002), which indicates a worse clinical course. These concepts give a better insight in the phenotypic prognosis of PMM2-CDG, according to their molecular base.
Keywords: NPCRS; PMM2-CDG; congenital disorders of glycosylation; genotype; mutation.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Genotype/Phenotype Relationship: Lessons From 137 Patients With PMM2-CDG.Hum Mutat. 2024 Oct 3;2024:8813121. doi: 10.1155/2024/8813121. eCollection 2024. Hum Mutat. 2024. PMID: 40225925 Free PMC article.
-
Goal attainment in PMM2-CDG: A new approach measuring meaningful clinical outcomes.Mol Genet Metab. 2025 May;145(1):109087. doi: 10.1016/j.ymgme.2025.109087. Epub 2025 Mar 19. Mol Genet Metab. 2025. PMID: 40121796
-
Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.Orphanet J Rare Dis. 2015 Oct 26;10:138. doi: 10.1186/s13023-015-0358-y. Orphanet J Rare Dis. 2015. PMID: 26502900 Free PMC article.
-
A comprehensive update of genotype-phenotype correlations in PMM2-CDG: insights from molecular and structural analyses.Orphanet J Rare Dis. 2025 Apr 30;20(1):207. doi: 10.1186/s13023-025-03669-5. Orphanet J Rare Dis. 2025. PMID: 40307862 Free PMC article. Review.
-
Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.J Med Genet. 2017 Dec;54(12):843-851. doi: 10.1136/jmedgenet-2017-104903. Epub 2017 Sep 27. J Med Genet. 2017. PMID: 28954837 Review.
Cited by
-
Cysteine Pathogenic Variants of PMM2 Are Sensitive to Environmental Stress with Loss of Structural Stability.Oxid Med Cell Longev. 2023 Jan 25;2023:5964723. doi: 10.1155/2023/5964723. eCollection 2023. Oxid Med Cell Longev. 2023. PMID: 36743691 Free PMC article.
-
Phosphomannomutase 2-congenital disorder of glycosylation: exploring the role of N-glycosylation on the endocrine axes.Front Endocrinol (Lausanne). 2025 Jul 23;16:1594118. doi: 10.3389/fendo.2025.1594118. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40771275 Free PMC article. Review.
-
Phosphomannomutase 2 hyperinsulinemia: Recent advances of genetic pathogenesis, diagnosis, and management.Front Endocrinol (Lausanne). 2023 Jan 16;13:1102307. doi: 10.3389/fendo.2022.1102307. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36726472 Free PMC article. Review.
-
Acetazolamide treatment in late onset CDG type 1 due to biallelic pathogenic DHDDS variants.Mol Genet Metab Rep. 2022 Jul 25;32:100901. doi: 10.1016/j.ymgmr.2022.100901. eCollection 2022 Sep. Mol Genet Metab Rep. 2022. PMID: 36046393 Free PMC article.
-
[Advances in the diagnosis and treatment of phosphomannomutase 2 deficiency].Zhongguo Dang Dai Er Ke Za Zhi. 2023 Feb 15;25(2):223-228. doi: 10.7499/j.issn.1008-8830.2209049. Zhongguo Dang Dai Er Ke Za Zhi. 2023. PMID: 36854702 Free PMC article. Review. Chinese.
References
-
- Sparks S.E., Krasnewich D.M. PMM2-CDG (CDG-Ia) In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J., Stephens K., Mirzaa G., Amemiya A., editors. GeneReviews® [Internet] University of Washington; Seattle, WA, USA: 1993. [(accessed on 15 August 2021)]. [cited 2020 May 3] Available online: http://www.ncbi.nlm.nih.gov/books/NBK1110/
-
- Matthijs G., Schollen E., Pardon E., Veiga-Da-Cunha M., Jaeken J., Cassiman J.-J., Van Schaftingen E. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome) Nat. Genet. 1997;16:88–92. doi: 10.1038/ng0597-88. - DOI - PubMed
-
- Citro V., Cimmaruta C., Monticelli M., Riccio G., Hay Mele B., Cubellis M., Andreotti G. The Analysis of Variants in the General Population Reveals That PMM2 Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of Modifiers. Int. J. Mol. Sci. 2018;19:2218. doi: 10.3390/ijms19082218. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources